Biotech Business - October 31, 2023
Cantargia raises approximately SEK 59 million
The board of directors of Cantargia has resolved to carry out a directed new issue of 16,698,789 shares at a subscription price of SEK 3.55 per share. The Directed Share Issue will provide Cantargia with approximately SEK 59.3 million before deduction of transaction costs. Investors in the Directed Share Issue represent a variety of Swedish […]
Acquisition - October 30, 2023
Thermo Fisher Scientific to acquire Olink
Thermo Fisher Scientific and Olink Holding have announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for USD 26.00 per common share in cash, representing USD 26.00 per American Depositary Share (ADS) in cash. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common […]
Biotech Business - October 25, 2023
Nykode Therapeutics raises NOK 505 million
The company has announced that a Private Placement has been successfully placed, raising approximately NOK 505 million in gross proceeds through the allocation of 29,549,400 new shares at a subscription price of NOK 17.10 per share. “We are pleased with the strong support Nykode has received from a group of international specialist investors and our […]
Biotech Business - October 19, 2023
Venture forces invest 15 million DKK in Dania Therapeutics
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures, has made an investment in the Danish biotech company Dania Therapeutics. “We are stepping in with strong partners at an early stage, where we can help build and further develop Dania Tx. We know from previous collaborations that Kristian Helin stands […]
Agreement - October 16, 2023
Spark Therapeutics terminates agreement with CombiGene
CombiGene will regain the global rights for the epilepsy project CG01 from Spark Therapeutics by January 12, 2024. The collaboration agreement between CombiGene and Spark Therapeutics, which was signed in October 2021, shall be terminated because of a strategic decision by Spark Therapeutics to deprioritize the further development of CG01 in epilepsy as part of […]
Biotech Business - October 10, 2023
Pixelgen Technologies closes Series A financing
Pixelgen has closed a Series A financing of approximately USD 7.3 million. The round was led by new investor Industrifonden, Sweden’s venture capital fund, and Navigare Ventures, an investor in Pixelgen’s Seed round. Proceeds from the financing will support the commercial expansion of Pixelgen’s recently launched spatial proteomics tool for analyzing cell surface proteins on […]
